Tolimidone

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals is a clinical-stage biotechnology company leveraging proprietary drug delivery technologies to improve the performance of existing therapeutic agents. Its strategy centers on reformulating known drugs using nanotechnology and pH-sensitive polymers to enhance bioavailability and pharmacokinetics, thereby de-risking development. The company's pipeline is advancing towards a pivotal Phase 3 trial for eRapa in FAP, while also exploring molecular glue degraders for resistant cancers and a novel therapy for type 1 diabetes. With an experienced leadership team, Biodexa aims to address significant unmet needs in oncology and rare diseases.

About Melior Pharmaceuticals

Melior Pharmaceuticals is a private, pre-revenue biotech founded in 2005 that utilizes a unique drug repurposing platform to advance a de-risked clinical pipeline. Its lead assets are Tolimidone, a lyn kinase activator in Phase 2b for Type 2 Diabetes and early-stage for NASH, and Mesocarb, a dopamine reuptake inhibitor in development for Parkinson's Disease and Sleep Disorders. The company's strategy leverages existing clinical safety data to potentially accelerate development and reduce risk. Melior is seeking partnerships to advance its programs through later-stage clinical trials.

About Melior Pharmaceuticals

Melior Pharmaceuticals is a private, pre-revenue biotech founded in 2005 that utilizes a unique drug repurposing platform to advance a de-risked clinical pipeline. Its lead assets are Tolimidone, a lyn kinase activator in Phase 2b for Type 2 Diabetes and early-stage for NASH, and Mesocarb, a dopamine reuptake inhibitor in development for Parkinson's Disease and Sleep Disorders. The company's strategy leverages existing clinical safety data to potentially accelerate development and reduce risk. Melior is seeking partnerships to advance its programs through later-stage clinical trials.

Therapeutic Areas

Other Type 2 Diabetes Drugs